Botulinum toxin for chronic anal fissure after biliopancreatic diversion for morbid obesity

Table 1 Parameters considered in the analysis of 59 patients who were treated with botulinum toxin for chronic anal fissure and had previously undergone biliopancreatic diversion

	Frequency	Percent (%)
Age (yr)
≤ 30	12	20.3
31-40	19	32.2
41-50	15	25.4
> 50	13	22.0
Sex
Female	38	64.4
Male	21	35.6
Duration of symptoms (mo)
≤ 7	31	52.5
> 7	28	47.5
Postdefecatory anal pain
Present	58	98.3
Absent	1	1.7
Nocturnal anal pain
Present	17	28.8
Absent	42	71.2
Anal pain unrelated to defecation
Present	22	37.3
Absent	37	62.7
Bleeding
Present	44	74.6
Absent	15	25.4
Mucorrhea
Present	13	22.0
Absent	46	78.0
Other anal pathologies
Present	7	11.9
Absent	52	88.1
Extra-anal pathologies
Present	23	39.0
Absent	36	61.0
Defecation pattern
Normal	5	8.5
Diarrhea	50	84.7
Constipation	4	6.8
Stool consistency
Formed	5	8.5
Soft	50	84.7
Hard	4	6.8
Number of evacuations per week
≤ 7	6	10.2
> 7	53	89.8
Straining
Present	3	5.1
Absent	56	94.9
Incomplete evacuations
Present	3	5.1
Absent	56	94.9
Laxative use
Yes	3	5.1
No	56	94.9
Enemas/suppositories use
Yes	3	5.1
No	56	94.9
Location of fissure
Posterior midline	54	91.5
Anterior midline	3	5.1
Others	2	3.4